ArticleFrontiers in endocrinology2025
Association of baseline and longitudinal plasma retinol-binding protein 4 with all-cause mortality in maintenance hemodialysis patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Elevated levels of retinol-binding protein 4 (RBP4) have been linked to conditions including cardiovascular disease, type 2 diabetes, obesity, and insulin resistance. However, the associations between baseline and longitudinal RBP4 levels with all-cause mortality in maintenance hemodialysis patients remain uncertain. The aim of this study was to investigate this issue. Methods: A total of 342 consecutive patients undergoing maintenance hemodialysis at a single hemodialysis center between 2010 and 2022 were assessed. Enzyme-linked immunosorbent assay was used to quantify plasma RBP4 concentrations. Patient outcomes were assessed using Cox regression and Kaplan-Meier analyses. Results: Non-survivors were associated with significantly lower baseline and longitudinal RBP4 levels compared to the survivors. A trend toward reduced all-cause mortality was found across quartiles of baseline and longitudinal RBP4 levels (p for trend < 0.0001). Multivariate analysis showed that the patients in the lowest quartiles (Quartile 1) of baseline and longitudinal RBP4 levels had hazard ratios of 2.22 (95% CI: 1.16-4.31) and 2.44 (95% CI: 1.30-4.84) for all-cause mortality, respectively, compared to those in the fourth quartile. In contrast to the non-survivors, the survivors had significantly higher plasma RBP4 levels during the 1-year follow-up period compared to the levels at the initiation of hemodialysis (p = 0.001). In addition, a positive association was observed between baseline RBP4 concentration and albumin level, while negative associations were observed between baseline RBP4 concentration and levels of aspartate aminotransferase, high-sensitivity C-reactive protein, and mean corpuscular volume. Structural equation model analysis confirmed the effect of RBP4 on mortality. Discussion: Associations were identified between low baseline and longitudinal RBP4 plasma concentrations and all-cause mortality in our cohort of Taiwanese maintenance hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.